GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Price-to-Free-Cash-Flow

Peptron (XKRX:087010) Price-to-Free-Cash-Flow : N/A (As of Sep. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Peptron Price-to-Free-Cash-Flow?

As of today (2024-09-23), Peptron's share price is ₩53900.00. Peptron's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-651.60. Hence, Peptron's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Peptron's Price-to-Free-Cash-Flow or its related term are showing as below:

XKRX:087010's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 36.415
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Peptron's Free Cash Flow per Share for the three months ended in Jun. 2024 was ₩-174.59. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was ₩-651.60.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 16.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.30% per year.

During the past 10 years, Peptron's highest 3-Year average Free Cash Flow per Share Growth Rate was 16.60% per year. The lowest was -55.60% per year. And the median was 10.60% per year.


Peptron Price-to-Free-Cash-Flow Historical Data

The historical data trend for Peptron's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Price-to-Free-Cash-Flow Chart

Peptron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Peptron Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Peptron's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Peptron's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peptron's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peptron's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Peptron's Price-to-Free-Cash-Flow falls into.



Peptron Price-to-Free-Cash-Flow Calculation

Peptron's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=53900.00/-651.603
=N/A

Peptron's Share Price of today is ₩53900.00.
Peptron's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-651.60.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Peptron  (XKRX:087010) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Peptron Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Peptron's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Peptron Business Description

Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron Headlines

No Headlines